Yyyyyy x. yyyyyy

0000 xxxxxx xxxx , xxxx , xxxxx 00000 ● (xxx-xxx-xxxx ● abc@xyz.com

Biological Engineering ~ Chemical Engineering ~ Material Science

         Well-versed in biopharmaceutical industry with an emphasis on development, manufacturing, and evaluation of cutting-edge biologic therapeutics to treat multiple types of carcinomas.

         Proficiency in bacterial/mammalian cell culture development and maintenance, protein engineering, data analysis, comprehensive report writing, and SOP development.

         Adept at using structured methodologies for upstream process design, process control strategies, validation, and continuous process verification specific to mammalian-expressed proteins.

         Self-motivated, collaborative, and highly adaptable with strong presentation and communication skills.

         Bilingual (English & Mandarin) with considerable project management talents; proven success in coaching, mentoring, and supervising research teams in completing projects within timeline and budget parameters.

         Proficiency in designing and conducting experiments, analyzing and interpreting results, and recommending changes or additional experiments in support of goal attainment.

         Highly capable of improving methods for production, purification, and testing of new process formulas, technologies, and associated implementation in manufacturing/QC facilities.

            Dynamic Light Scattering

            Zeta Potential Measurement

            Nanoparticle Tracking Analysis

            Spectroscopy

            Chromatography

            Gel Electrophoresis

            Filter Membrane Selection

         Plasmid Construction

         Medium Development

         Temperature/Oxygen Control

         Expression Optimization

         Stable Cell Line Generation

         mRNA Analysis by Real-time PCR

         Flow Cytometry

Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 2015-Present

Postdoctoral Research Associate

         Established upstream processes for complex protein production in support of Recombinant Peptide-based Gene Delivery Vector Development project.

         Leverage exceptional attention to detail in performing mammalian and bacterial system selection and maintenance.

         Systematically administer peptide sequence optimization and plasmid construction including backbone and promoter selection, gene clone, purification, and endotoxin removal.

         Perform nucleotides/vector complex formation and characterization, and meticulously document findings.

         Effectively prepare storage buffer formulation to enhance peptide and complex stability.

         Methodically create vehicle buffer and transfection media formulation to facilitate nucleotides delivery.

         Resourcefully employ methods such as WST-1 assay, LDH (lactate dehydrogenase), Genotoxicity and mRNA real-time PCR assay to conduct toxicity evaluation.

         Generate stable cell line encompassing recombination, transposon, and lentivirus, and high-producing clone selection.

         Demonstrate proficiency in media development, temperature and oxygen control, induction strategy, and expression optimization to facilitate fermentation, scale-up, and manufacturing functions.

Continued ►

Professional Experience (Rutgers) continued Page 2 of 2

         Use process of chromatography to perform protein purification, and implement rigorous quality assurance and control procedures with specific attention to yield and purity factors.

         Created multiple formulations to support nucleotides delivery using recombinant peptides which resulted in highly efficient and low toxic gene delivery system with associated bio-process.

         Successfully authored two peer-reviewed articles, co-authored three peer-reviewed articles, one book chapter, and one patent.

Department of Chemical & Biomolecular Engineering, Tulane University, New Orleans, LA, 2009-2014

Ph.D. Candidate

         Conceived cancer-targeted suicide gene therapeutic delivered by polycationic polymer in support of Non-Viral Gene and Cell Therapy for Bladder Tumor Treatment project.

         Engineered formulation based on Polyethylenimine to simplify in vitro and in vivo gene delivery.

         Utilized flow cytometry to evaluate in vitro efficacy and safety factors, and conducted in vivo preclinical evaluation based on murine tumor model.

         Developed bacterial-derived cell therapeutic currently under commercialization and featuring an efficient polycationic polymer suicide gene therapy system with in vivo safety and efficacy.

         Authored three peer-reviewed articles and one book chapter, and co-authored one peer-reviewed article.

         Delivered influential mentoring and guidance to three undergraduates, a Pharm.D. student, two graduate students, and a lab technician.

Ph.D., Chemical and Biomolecular Engineering, Tulane University, New Orleans, LA, US, 2014

Master, Chemical Engineering, Dalian University of Technology, Dalian, China, 2009

Professional Development:

SciPhD, The Business of Science for Scientists, Rutgers University, New Brunswick, NJ

Project Management Certification Training, Career Academy, Needham, MA

(Full list provided upon request)

Chen X., Normani A., Patel, N., Hatefi A., Production of Low-Expressing Recombinant Cationic Biopolymers with High Purity. Protein Expression and Purification (2017) (Accepted)

Chen X., Normani A., Patel, N., Hatefi A., Development of an Efficient and Safe Non-Viral Recombinant Vector for Transfection of Adipose-Derived Mesenchymal Stem Cells. (In preparation)

Chen X., Scapa J., Liu D., and Godbey WT. Cancer-specific Promoters for Expression-targeted Gene Therapy: ran, brms1, and mcm5. Journal of Gene Medicine (2016) 18: 89 101.

Chen X. and Godbey WT. The potential of the osteopontin promoter and single-nucleotide polymorphisms for targeted cancer gene therapy. Current Gene Therapy, (2015), 15(1): 82-92

Tsuji, S., Chen, X. (co-first authorship), Hancock, B., Hernandez, V., Visentin, B., Reil, K., Sabbadini, R., Giacalone, M., Godbey, WT. Pre-clinical Evaluation of VAX-IP, a Novel Bacterial Minicell-Based Biopharmaceutical for Non-Muscle Invasive Bladder Cancer. Molecular Therapy Oncolytics (2016) 3: 16004.

American Institute of Chemical Engineers

American Society of Gene & Cell Therapy